Antitumor T-cell Immunity Contributes to Pancreatic Cancer Immune Resistance
Reham Ajina,Zoe X Malchiodi,Allison A Fitzgerald,Annie Zuo,Shangzi Wang,Maha Moussa,Connor J Cooper,Yue Shen,Quentin R Johnson,Jerry M Parks,Jeremy C Smith,Marta Catalfamo,Elana J Fertig,Sandra A Jablonski,Louis M Weiner,Zoe X. Malchiodi,Allison A. Fitzgerald,Connor J. Cooper,Quentin R. Johnson,Jerry M. Parks,Jeremy C. Smith,Elana J. Fertig,Sandra A. Jablonski,Louis M. Weiner
DOI: https://doi.org/10.1158/2326-6066.CIR-20-0272
IF: 10.1
2021-04-01
Cancer Immunology Research
Abstract:Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer death in the United States. Pancreatic tumors are minimally infiltrated by T cells and are largely refractory to immunotherapy. Accordingly, the role of T-cell immunity in pancreatic cancer has been somewhat overlooked. Here, we hypothesized that immune resistance in pancreatic cancer was induced in response to antitumor T-cell immune responses and that understanding how pancreatic tumors respond to immune attack may facilitate the development of more effective therapeutic strategies. We now provide evidence that T-cell–dependent host immune responses induce a PDAC-derived myeloid mimicry phenomenon and stimulate immune resistance. Three KPC mouse models of pancreatic cancer were used: the mT3-2D (Kras +/LSL-G12D ; Trp53 +/LSL-R172H ; Pdx1-Cre) subcutaneous and orthotopic models, as well as the KP1 (p48- CRE / LSL - Kras /Trp53 flox/flox ) subcutaneous model. KPC cancer cells were grown in immunocompetent and immunodeficient C57BL/6 mice and analyzed to determine the impact of adaptive immunity on malignant epithelial cells, as well as on whole tumors. We found that induced T-cell antitumor immunity, via signal transducer and activator of transcription 1 (STAT1), stimulated malignant epithelial pancreatic cells to induce the expression of genes typically expressed by myeloid cells and altered intratumoral immunosuppressive myeloid cell profiles. Targeting the Janus Kinase (JAK)/STAT signaling pathway using the FDA-approved drug ruxolitinib overcame these tumor-protective responses and improved anti–PD-1 therapeutic efficacy. These findings provide future directions for treatments that specifically disable this mechanism of resistance in PDAC.
oncology,immunology